Progress in the relationship between type II alveolar epithelial cells and idiopathic pulmonary fibrosis

doi:10.3877/cma.j.issn.2095-1221.2019.05.008

Abstract

Abstract:

Pulmonary fibrosis is a chronic disease of the lower respiratory tract that seriously affects lung ventilation and ventilation. The pathogenesis is still unclear. It is characterized by abnormal interstitial inflammation and fibrosis, and destruction of alveolar structure. Type Ⅱ alveolar epithelial cells, as key cells of maintaining lung structure and function, are extremely important in the development and progression of pulmonary fibrosis. In pulmonary fibrosis, damage to typeⅡ alveolar epithelial cells and senescence apoptosis caused by various causes may be the initiation factors of pulmonary fibrosis. After that, abnormal typeⅡ alveolar epithelial cells are also involved and in the formation of temporary matrix, fibroblast aggregation, activation and interstitial-epithelial transformation, play an important role.

Key words: Type II alveolar epithelial cells, Pulmonary fibrosis, Apoptosis

Yukun Yang, Ye Li, Xiangqing Zhu, Yin Lei, Yanying Wang, Chuan Tian, Guangping Ruan, Xinghua Pan. Progress in the relationship between type II alveolar epithelial cells and idiopathic pulmonary fibrosis[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(05): 304-308.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2019.05.008

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2019/V09/I05/304

References 49

[1]	Beers MF, Moodley Y. When is an alveolar type 2 cell an alveolar type 2 cell? a conundrum for lung stem cell biology and regenerative medicine[J]. Am J Respir Cell Mol Biol, 2017, 57(1):18-27.
[2]	Guillot L, Nathan N, Tabary O, et al. Alveolar epithelial cells: master regulators of lung homeostasis[J]. Int J Biochem Cell Biol, 2013, 45(11):2568-2573.
[3]	Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis[J]. Semin Resp Crtt Care, 2011, 378(9807):1949.
[4]	Geiser T. Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair?[J]. Swiss Med Wkly, 2003, 133(29/30):405-411.
[5]	Crapo JD, Young SL, Fram EK, et al. Morphometric characteristlcs of cells in the alveolar region of mammalian lungs[J]. Am Rev Respir Dis, 1983, 128(2 Pt 2):S42-46.
[6]	Baritussio AG, Magoon MW, Goerke J. Precursor-product relationship between rabbit typeⅡcell lamellar bodies and alveolar surface-active material.Surfactant turnover time[J]. Biochim Biophys Acta, 1981, 666(3):382-393.
[7]	Mason RJ. Biology of alveolar typeⅡcells[J]. Respirology, 2006, 11(S):S12-S15.
[8]	Lopez-Rodriguez E, Pérez-Gil J. Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy[J]. Biochim Biophys Acta, 2014, 1838(6):1568-1585.
[9]	Guth AM, Janssen WJ, Bosio CM, et al. Lung environment determines unique phenotype of alveolar macrophages[J]. Am J Physiol Lung Cell Mol Physiol, 2009, 296(6):L936-L946.
[10]	Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context[J]. Nat Rev Immunol, 2014, 14(2):81-93.
[11]	O'Brien AD, Standiford TJ, Christensen PJ, et al. Chemotaxis of alveolar macrophages in response to signals derived from alveolar epithelial cells[J]. J Lab Clin Med,1998,131(5):417-424.
[12]	Fehrenbach H. Alveolar epithelial typeⅡcell: defender of the alveolus revisited[J]. Respir Res, 2001, 2(1):33-52.
[13]	Minoo P, King RJ. Epithelial-mesenchymal interactions in lung development[J]. Annu Rev Physiol, 1994, 56:13-45.
[14]	Haschek WM, Witschi H. Pulmonary fibrosis--a possible mechanism[J]. Toxicol Appl Pharmacol, 1979, 51(3):475-487.
[15]	Barbas-Filho JV, Ferreira MA, Sesso A, et al. Evidence of typeⅡ pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis(IFP)/usual interstitial pneumonia(UIP)[J]. J Clin Pathol, 2001, 54(2):132-138.
[16]	Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2010, 181(3):254-263.
[17]	Tanjore H, Blackwell TS, Lawson WE. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(8):L721-L729.
[18]	Maitra M, Wang YY, Gerard RD, et al. Surfactant protein a2 mutations associated with pulmonary fibrosis Lead to protein instability and endoplasmic reticulum stress[J]. J Biol Chem, 2010, 285(29):22103-22113.
[19]	Nogee LM, Dunbar AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease[J]. N Engl J Med, 2001, 344(8):573-579.
[20]	Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(6):L1119-L1126.
[21]	Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2008, 178(8):838-846.
[22]	Mulugeta S, Nguyen V, Russo SJ, et al. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation[J]. Am J Respir Cell Mol Biol, 2005, 32(6):521-530.
[23]	Mulugeta S, Maguire JA, Newitt JL, et al. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms[J]. Am J Physiol Lung Cell Mol Physiol, 2007, 293(3):L720-L729.
[24]	Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs[J]. Proc Natl Acad Sci U S A, 2011, 108(26):10562-10567.
[25]	O'Dwyer DN, Ashley SL, Moore BB. Influences of innate immunity, autophagy and fibroblast activation in the pathogenesis of lung fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2016, 11(3):L590-601.
[26]	Wang K, Zhang T, Lei YL, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux[J]. Autophagy, 2018, 14(2):269-282.
[27]	Tomohiro Y, Usha N, Zhifen Y, et al. Endoplasmic reticulum stress triggers autophagy[J]. J Biol Chem, 2006, 281(40):30299-30304.
[28]	Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis[J]. J Clin Invest, 2015, 125(2):521-538.
[29]	Birkelbach B, Lutz D, Ruppert C, et al. Linking progression of fibrotic lung remodeling and ultrastructural alterations of alveolar epithelial typeⅡcells in the amiodarone mouse model[J]. Am J Physiol Lung Cell Mol Physiol, 2015, 309(1):L63-L75.
[30]	Mahavadi P, Knudsen L, Venkatesan S, et al. Regulation of macroautophagy in amiodarone-induced pulmonary fibrosis[J]. J Pathol Clin Res, 2015, 1(4):252-263.
[31]	Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2007, 356(13):1317-1326.
[32]	Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase[J]. Proc Natl Acad Sci U S A, 2007, 104(18):7552-7557.
[33]	Camelo A, Dunmore R, Sleeman MA, et al. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier[J]. Front Pharmacol, 2014, 4:173.
[34]	Caja L, Dituri F, Mancarella S, et al. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer[J]. Int J Mol Sci, 2018, 19(5): pii: E1294.
[35]	Knudsen L, Lopez-Rodriguez E, Berndt L, et al. Pressure dependent alveolar derecruitment is linked with surfactant dysfunction in Bleomycin-Induced acute lung injury[J]. Am J Respir Crit Care Med, 2016, 193:A4813.
[36]	Knudsen L, Ruppert C, Ochs M. Tissue remodelling in pulmonary fibrosis[J]. Cell Tissue Res, 2017, 367(3):607-626.
[37]	Funke M, Zhao ZW, Xu Y, et al. The lysophosphatidic acid receptor LPA(1) promotes epithelial cell apoptosis after lung injury[J]. Am J Respir Cell Mol Biol, 2012, 46(3):355-364.
[38]	Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease[J]. Nat Med, 2012, 18(7):1028-1040.
[39]	Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22):2071-2082.
[40]	Günther S, Bordenave J, Hua-Huy T, et al. Macrophage migration inhibitory factor (MIF) inhibition in a murine model of Bleomycin-Induced pulmonary fibrosis[J]. Int J Mol Sci, 2018, 19(12): pii: E4105.
[41]	Cao ZW, Lis R, Ginsberg M, et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis[J]. Nat Med, 2016, 22(2):154-162.
[42]	Wynn TA. Integrating mechanisms of pulmonary fibrosis[J]. J Exp Med, 2011, 208(7):1339-1350.
[43]	Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?[J]. Br J Pharmacol, 2008, 153(Suppl 1):S367-S378.
[44]	Jagadapillai R, Rane MJ, Lin X, et al. Diabetic microvascular disease and pulmonary fibrosis: the contribution of platelets and systemic inflammation[J]. Int J Mol Sci, 2016, 17(11): pii: E1853.
[45]	Yang J, Wheeler SE, Velikoff M, et al. Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins[J]. Am J Pathol, 2013, 183(5):1559-1570.
[46]	Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis:from innocent targets to serial killers[J]. Proc Am Thorac Soc, 2006, 3(4):364-372.
[47]	Andersson-Sjöland A, De Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis[J]. Int J Biochem Cell Biol, 2008, 40(10):2129-2140.
[48]	Heukels P, Van Hulst J, Van Nimwegen M, et al. Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis[J]. Respir Res, 2018, 19(1):90.
[49]	Margaritopoulos GA, Giannarakis I, Siafakas N. An update on idiopathic pulmonary fibrosis[J]. Panminerva Med, 2013, 55(2):109-120.

Please choose a citation manager

Content to export